ArticleCureus2025
Pseudohyperkalemia as a New Insight Into the Causes of Hyperkalemia Associated With Atopic Dermatitis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudohyperkalemia is defined as a falsely elevated serum potassium level caused by the release of potassium from blood cells during the clotting process, which occurs in vitro. Although hyperkalemia, a potentially life-threatening condition, has been associated with severe atopic dermatitis (AD) through mechanisms such as the 'aldosterone paradox,' pseudohyperkalemia has not been documented in AD. We present a case of pseudohyperkalemia in a nine-month-old girl with thrombocytosis associated with severe AD. Despite a serum potassium level of 7.3 mEq/L, the whole-blood potassium measured using a blood gas analyzer was 4.8 mEq/L. Therefore, we diagnosed the case as pseudohyperkalemia and decided not to treat the serum hyperkalemia. Following treatment with topical steroids and a Janus kinase inhibitor, the pseudohyperkalemia resolved as the skin condition improved and the platelet count decreased.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.